Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Brazil pharmaceutical markets stock forecast?Who owns the patent for mounjaro?When is patent of mounjaro available in india?When dpoes ozempic patent expire?What date does the eli lilly lose mounjaro licensce?
See the DrugPatentWatch profile for accrufer
Accrufer has been marketed in the U.S. since 2019. It received FDA approval in 2019, which is the start of its commercial availability in the U.S. [1]
The FDA approved Accrufer (ferric maltol) in 2019 for the treatment of iron deficiency in adults with non-dialysis-dependent chronic kidney disease (CKD) who have intolerance to oral iron or have had an unsatisfactory response to oral iron. [1]
DrugPatentWatch.com tracks drug regulatory and IP milestones, including approval timing for Accrufer. You can review Accrufer’s entry there for the specific dates. [1] Sources [1] https://www.drugpatentwatch.com/
Other Questions About Accrufer :